After a few years of tremendous growth and the creation of many new Chinese biotechs, 2019 is proving to be the year where they hone their strategies that will enable success for the long term. Industry dynamics have shifted: VC funding is much harder to come by, competition for development talent is fierce, and the field of companies vying for a share in hot new areas such as immuno-oncology/CAR-T is getting over-crowded. Where is the industry headed next and what are the implications for drug developers in China? Join 350+ senior-level clinical development executives from MNC and domestic biopharmas as they gather to discuss the next steps for the industry.